Pontault Combault, France

Olivier Neckebrock



 

Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 29(Granted Patents)


Location History:

  • Ponteau Combault, FR (2006)
  • Pontault Combault, FR (2011 - 2016)

Company Filing History:


Years Active: 2006-2016

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Olivier Neckebrock: Innovator in Optical Enantiomers

Introduction

Olivier Neckebrock is a notable inventor based in Pontault Combault, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of optical enantiomers. With a total of 5 patents to his name, Neckebrock's work has advanced the understanding and application of modafinil.

Latest Patents

Neckebrock's latest patents focus on the preparation and crystalline forms of optical enantiomers of modafinil. One of his inventions relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum with intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 Å. Another patent describes a polymorphic form of (−)-modafinil that yields a spectrum with intensity peaks at interplanar spacings of approximately 14.14, 10.66, 7.80, and 4.02 Å. These innovations are crucial for enhancing the efficacy and stability of modafinil formulations.

Career Highlights

Throughout his career, Neckebrock has worked with prominent companies in the pharmaceutical industry, including Teva Santé and Cephalon France. His experience in these organizations has allowed him to collaborate on various projects that push the boundaries of pharmaceutical research and development.

Collaborations

Neckebrock has had the opportunity to work alongside esteemed colleagues such as Pierre Leproust and Laurent Courvoisier. These collaborations have contributed to the successful development of his patented technologies.

Conclusion

Olivier Neckebrock's contributions to the field of optical enantiomers and his innovative patents reflect his dedication to advancing pharmaceutical science. His work continues to influence the industry and improve therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…